Drugs / FYTF-919
FYTF-919
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT05066620 | Oct 2021 → Dec 2024 | intracerebral hemorrhage | Guangzhou University of Traditional Chinese Medicine | Unknown | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT05483595 | Sep 2022 → Jun 2023 | — | Guangzhou University of Traditional Chinese Medicine | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FYTF-919 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05066620 ↗ |
| Known as | Zhong Feng Xing Nao (ZFXN) prescription | “Zhong Feng Xing Nao (ZFXN) prescription” NCT05483595 ↗ |
| Known as | Zhongfeng Xingnao | “The traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao) in an oral solution is comprised of several Chinese herbs that are widely used to treat patients with...” PMID 39547249 ↗ Nov 2024 |
| Modality | Traditional medicine (herbal / TCM) | “traditional Chinese medicine FYTF-919” PMID 39547249 ↗ Nov 2024 |
| Route | Oral | “oral liquid FYTF-919” PMID 39547249 ↗ Nov 2024 |